November 3, 2023 in KVA1213 Publications

VISTA-101: A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA alone and in combination with pembrolizumab in advanced solid tumors

Thierry Guillaudeux, Phd, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2023 | November 3, 2023

Read More
September 15, 2023 in KVA1213 Publications

Frontiers in Oncology : Clinical and Research Updates on the VISTA Immune Checkpoint: Immuno-oncology Themes and Highlights

Randolph J. Noelle, J. Louise Lines, Lionel D. Lewis, Robert E. Martell, Thierry Guillaudeux, Sam W. Lee, Kathleen M. Mahoney, Matthew D. Vesely, Jerome Boyd-Kirkup, Dhanya K. Nambiar and Andrew M. Sc ...

Read More